Axsome Therapeutics, Inc. Common Stock Earnings Dividend

Axsome Therapeutics, Inc. Common Stock’s revenue jumped 45.54% since last year same period to $218.38Mn in the Q2 2026. On a quarterly growth basis, Axsome Therapeutics, Inc. Common Stock has generated 14.21% jump in its revenue since last 3-months.

Axsome Therapeutics, Inc. Common Stock’s net profit fell -6.96% since last year same period to $-51.31Mn in the Q2 2026. On a quarterly growth basis, Axsome Therapeutics, Inc. Common Stock has generated 20.5% jump in its net profits since last 3-months.

Axsome Therapeutics, Inc. Common Stock’s net profit margin jumped 26.51% since last year same period to -23.5% in the Q2 2026. On a quarterly growth basis, Axsome Therapeutics, Inc. Common Stock has generated 30.39% jump in its net profit margins since last 3-months.

Axsome Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.99 - a -15.12% fall from last quarter’s estimates.

Axsome Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.99.

Axsome Therapeutics, Inc. Common Stock’s earning per share (EPS) fell -2.06% since last year same period to -0.99 in the Q2 2026. This indicates that the Axsome Therapeutics, Inc. Common Stock has generated -2.06% annual rate of fall in its earning per share (EPS) in the last 4 quarters.